Results 11 to 20 of about 5,265 (145)

A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019

New Microbes and New Infections, 2021
Sofosbuvir and daclatasvir have been used successfully since 2013 for hepatitis C treatment. It has been shown by different studies that sofosbuvir can inhibit RNA polymerase of other positive-strand RNA viruses including Flaviviridae and Togaviridae ...
M. Shabani, B. Sadegh Ehdaei, F. Fathi, R. Dowran   +3 more
doaj   +2 more sources

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection [PDF]

, 2017
BACKGROUND: Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained virologic response after treatment with regimens containing direct-acting antiviral agents (DAAs) have limited retreatment options. METHODS: We
Bansal, Meena B, Michael P. Manns, Stephen Pianko, Younes, Ziad, Mchutchison, John, G., Landis, Charles, S, Natarajan Ravendhran, Robert H. Hyland, Flamm, Steven L, Cooper, Curtis, Younes, Ziad H, Tran, Tram, Curry, Michael, Tran, Tram T, Manns, Michael, Huang, K.C., Huang, K C, Reddy, K R, Schiff, Eugene, Curtis L. Cooper, Jie Zhang, Brainard, Diana M, Simone I. Strasser, Michael P. Curry, Steven L. Flamm, Pianko, Stephen, Svarovskaia, Evguenia, Charles S. Landis, Peter Buggisch, Buggisch, Peter, Diana M. Brainard, G. Mani Subramanian, Stamm, Luisa, Stuart C. Gordon, Marc Bourlière, Zhang, Jie, Flamm, Steven, L., Kowdley, Kris, V., John G. McHutchison, Bourlière, Marc, Ravendhran, Natarajan, Hadas Dvory-Sobol, Curry, Michael P, Stefan Zeuzem, Luisa M. Stamm, Brainard, Diana, K. Rajender Reddy, Tram T. Tran, Eugene R. Schiff, Alnoor Ramji, Evguenia Svarovskaia, McHutchison, John G, Vierling, John, Ramji, Alnoor, Reddy, K. Rajender, Subramanian, G. Mani, Kris V. Kowdley, Subramanian, G M, Cooper, Curtis L, Dvory-Sobol, Hadas, Hyland, Robert, John M. Vierling, Huang, K.C, Verna, Elizabeth C, Strasser, Simone I, Bansal, Meena, Victor de Lédinghen, K.C. Huang, de Lédinghen, Victor, Landis, Charles S, Elizabeth C. Verna, Subramanian, G Mani, Hyland, Robert H, Stamm, Luisa M, Gordon, Stuart, Myron Tong, Meena B. Bansal, Ziad H. Younes, Kowdley, Kris V, Reddy, K Rajender, Gordon, Stuart C, Strasser, Simone, Verna, Elizabeth, Manns, Michael P, Tong, Myron, Schiff, Eugene R, Vierling, John M, Zeuzem, Stefan   +87 more
core   +3 more sources

Cardiac Harms of Sofosbuvir: Systematic Review and Meta-Analysis [PDF]

, 2018
INTRODUCTION: Sofosbuvir is a new direct-acting pyrimidine nucleotide analogue antiviral drug that has shown remarkable efficacy in the treatment of hepatitis C in clinical trials.
Duarte, MM, Sterrantino, C, Barra, M, Gonçalves, N, Ferreira, JJ, Rodrigues, FB, Pinto, FJ, Costa, J, Caldeira, D   +8 more
core   +3 more sources

Development and Validation of RP-HPLC Method for the estimation of Sofosbuvir and Ledipasvir in combined dosage form

International Journal of Research in Pharmaceutical Sciences, 2021
Nowadays scientists aim at developing generic and specific methods for drugs in combined pharmaceutical dosage forms. The main aim was to develop and carry out validation using precision and accuracy for Sofosbuvir and Ledipasvir by applying RP-HPLC ...
Naik Desai Prabhat Prabhaker, Kapupara Pankaj   +1 more
doaj   +1 more source

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D

Pakistan Armed Forces Medical Journal, 2020
Objective: To assess the safety and efficacy of Sofosbuvir based Antiviral regimens for chronic hepatitis C virus infected patients with chronic kidney disease stage 3 to stage 5D on haemodialysis. Study Design: Quasi experimental study.
Nauman Kashif, Zahid Farooq Baig, Shahzad Ashraf   +2 more
doaj   +4 more sources

Efficacy and Adverse Effects of Sofosbuvir-Based Therapies (Double and Triple Regimens) in Chronic HCV Patients [PDF]

Afro-Egyptian Journal of Infectious and Endemic Diseases, 2017
Background and study aim: Egypt has the highest prevalence of hepatitis C virus in the world and it is about14.7 %. Until 2012, the combination of pegylated interferon-α and ribavirin was the standard of care in CHC.
Amal Jouda, Hosam Dawod, Nahla Elgammal
doaj   +1 more source

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

Journal of Virus Eradication, 2020
Objectives: Seven years after the introduction of direct-acting antivirals (DAAs) for the treatment of hepatitis C, high prices remain a barrier for treatment programs worldwide.
Melissa J. Barber, Dzintars Gotham, Giten Khwairakpam, Andrew Hill   +3 more
doaj   +1 more source

The outcome of the sofosbuvir Based Therapy in the treatment of Hepatitis C Virus Genotype 4 in Egyptian patients [PDF]

African Journal of Gastroenterology and Hepatology, 2019
Background and aim There have been significant advancements during the last few years, with large numbers of ongoing trials with various direct-acting antivirals (DAA) showing high potency against the hepatitis C virus (HCV).
Waleed Ismail, Amr Hanafy, Mohammed Abdelsattar   +2 more
doaj   +1 more source

The outcome of Daclatasvir and low dose Sofosbuvir therapy in end-stage renal disease patients with hepatitis C virus infection

Український Журнал Нефрології та Діалізу, 2020
Rapid progression of chronic kidney disease (CKD) is seen in patients with hepatitis C virus (HCV) infection compared with uninfected patients. Despite the high efficacy of direct-acting antivirals (DAAVs), their cost represents a limiting factor to ...
M. Mostafi, M. Jabin, Z. Chowdhury, M.U. Khondoker, S.M. Ali, R. Tamanna, R. Rezwan, S.B. Alomgir   +7 more
doaj   +1 more source

Virological Responses in Chronic Hepatitis C Patients, Treated with Sofosbuvir and Declacavir Versus Sofosbuvir and Ribazole [PDF]

, 2018
Objective: To determine the virological responses in chronic hepatitis c patients, treated with sofosbuvir and declacavir versus sofosbuvir and ribavirin at tertiary care Hospital Study Design And Setting: This was a prospective comparative study and was
Ali Jamali, Anwar
core   +1 more source